Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

Multi-center Open Label, Non-comparative Observational Study of Irbesartan-Hydrochlorothiazide in the Treatment of Hypertension in Chinese Population

To analyse the control rate of irbesartan/hydrochlorothiazide(HCTZ) (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension.

Inclusion criteria:

• Systolic blood pressure < 180 mmHg
• 90 mmHg ≤ Diastolic blood pressure < 110 mmHg

Exclusion criteria:

• Pregnancy or lactation. Women of child bearing potential (not post-menopausal) should be using a reliable contraceptive method
• Known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular stenosis, etc.)
• Presence of clinically significant ventricular or supraventricular arrhythmias, or second or third degree atrioventricular block, or sick sinus syndrome
• ALAT[SGPT]>2 times of upper limit，
• ASAT[SGOT]>2 times of upper limit
• Patients with known renal disease
• Serum potassium > normal upper limit
• Uncontroled BD（FBG>10mmol/L or PBG>12.22mmol/L)
• Patients treated with tricyclic antidepressants
• Clinical hematological disease.
• Patients with a history of irbesartan, or hydrochlorothiazide sensitivity defined as irbesartan, or hydrochlorothiazide discontinuation due to medically significant adverse effects.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.